After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
Stocks Info
As a NASDAQ listed company, BMRN falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Biomarin Pharmaceutical Inc is $9.97B. A total of 2.61 million shares were traded on the day, compared to an average of 2.41M shares.
In the most recent transaction, Burkhart Erin sold 1,786 shares of BMRN for 59.31 per share on May 20 ’25. After the transaction, the GVP, Chief Accounting Officer now owns 14,173 company shares. In a previous transaction on May 20 ’25, Burkhart Erin bought 1,786 shares at 59.31 per share.
Among the insiders who sold shares, Hubbard Cristin disposed of 273 shares on May 02 ’25 at a per-share price of $64.92. This resulted in the EVP, Chief Commercial Officer holding 32,700 shares of BMRN after the transaction. In another insider transaction, Hubbard Cristin bought 273 shares at $64.92 per share on May 02 ’25.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, BMRN has a high of $73.51 and a low of $51.56.
As of this writing, BMRN has an earnings estimate of $0.94 per share for the current quarter. EPS was calculated based on a consensus of 16.0 estimates, with a high estimate of $1.2 per share and a lower estimate of $0.77. The company reported an EPS of $0.92 in the last quarter
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. BMRN’s latest balance sheet shows that the firm has $1.01B in Cash & Short Term Investments as of fiscal 2021. There were $1.09B in debt and $546.50M in liabilities at the time. Its Book Value Per Share was $31.53, while its Total Shareholder’s Equity was $4.27B.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BMRN is Buy with a score of 4.46.
